Biosimilars | Market Events and Forecast | Ophthalmology | 2022

In 2020, sales of branded biologics in ophthalmology reached over $8.50 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2020-2030 forecast period, reference brands Lucentis (ranibizumab) and Eylea (aflibercept) are set to lose patent protection, and biosimilars will enter the market and erode both patient share and drug prices. We present our forecasts for these two key reference brands and their biosimilars by molecule and region.

Login to access report